Connor Clark & Lunn Investment Management Ltd. Has $2.88 Million Stock Position in Organogenesis $ORGO

Key Points

• Connor Clark & Lunn Investment Management Ltd. increased its stake in Organogenesis by 45.3%, acquiring an additional 208,038 shares, bringing its total ownership to 667,529 shares valued at approximately $2.88 million.
• Several large investors have also been active in the stock, with 49.57% of Organogenesis shares now held by institutional investors.
• Organogenesis reported a loss per share of $0.09 for the last quarter, missing analysts' estimates, and had revenues of $101.01 million against a consensus estimate of $104.75 million.

Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Organogenesis (NASDAQ:ORGO - Free Report) by 45.3% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 667,529 shares of the company's stock after purchasing an additional 208,038 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned 0.53% of Organogenesis worth $2,884,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in ORGO. JPMorgan Chase & Co. raised its stake in shares of Organogenesis by 36.4% during the 4th quarter. JPMorgan Chase & Co. now owns 280,997 shares of the company's stock worth $899,000 after purchasing an additional 75,054 shares in the last quarter. Wells Fargo & Company MN raised its stake in shares of Organogenesis by 29.6% during the 4th quarter. Wells Fargo & Company MN now owns 41,471 shares of the company's stock worth $133,000 after purchasing an additional 9,464 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of Organogenesis by 31.3% during the 4th quarter. Renaissance Technologies LLC now owns 1,073,500 shares of the company's stock worth $3,435,000 after purchasing an additional 255,600 shares in the last quarter. Barclays PLC raised its stake in shares of Organogenesis by 17.0% during the 4th quarter. Barclays PLC now owns 110,915 shares of the company's stock worth $355,000 after purchasing an additional 16,106 shares in the last quarter. Finally, Mariner LLC bought a new stake in shares of Organogenesis during the 4th quarter worth approximately $123,000. Institutional investors own 49.57% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on ORGO. Cantor Fitzgerald increased their price target on Organogenesis from $7.00 to $9.00 and gave the company an "overweight" rating in a research note on Friday, August 8th. BTIG Research restated a "buy" rating on shares of Organogenesis in a research note on Tuesday, July 15th. Two analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $7.50.

Insider Buying and Selling

In other news, insider Lori Freedman acquired 142,379 shares of the firm's stock in a transaction on Thursday, June 5th. The shares were purchased at an average cost of $2.91 per share, with a total value of $414,322.89. Following the acquisition, the insider directly owned 837,437 shares in the company, valued at $2,436,941.67. This represents a 20.48% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Over the last quarter, insiders acquired 252,264 shares of company stock valued at $725,732. Corporate insiders own 33.00% of the company's stock.

Organogenesis Price Performance

NASDAQ ORGO traded up $0.0350 on Tuesday, reaching $4.6150. The stock had a trading volume of 133,959 shares, compared to its average volume of 1,443,292. The firm has a fifty day moving average of $4.19 and a two-hundred day moving average of $4.11. Organogenesis has a 1-year low of $2.45 and a 1-year high of $6.71. The company has a market cap of $585.45 million, a P/E ratio of -32.96 and a beta of 1.76.

Organogenesis (NASDAQ:ORGO - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.08). Organogenesis had a negative net margin of 1.92% and a negative return on equity of 0.37%. The firm had revenue of $101.01 million during the quarter, compared to analyst estimates of $104.75 million. Organogenesis has set its FY 2025 guidance at EPS. Research analysts predict that Organogenesis will post -0.07 EPS for the current fiscal year.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.